he Tarrytown, NY-based biotech Regeneron has signed a $315 million pact with Bedford, MA-based Ocular Therapeutix to develop a sustained release formulation of the Regeneron’s eye medication Eylea.

That formulation, if successful, will cut down on injection frequency in patients suffering from wet age-related macular degeneration or other retinal diseases.